Skip to main content
EXACT Therapeutics AS logo

EXACT Therapeutics AS — Investor Relations & Filings

Ticker · EXTX ISIN · NO0010852213 LEI · 2138006ZE5JAL39AGD55 OL Manufacturing
Open in API
Filings indexed 233 across all filing types
Latest filing 2021-11-18 Regulatory Filings
Country NO Norway
Listing OL EXTX

About EXACT Therapeutics AS

https://www.exact-tx.com/

EXACT Therapeutics AS is a clinical-stage biopharmaceutical company developing its proprietary technology platform, Acoustic Cluster Therapy (ACT®), for targeted therapeutic enhancement. The ACT® platform uses ultrasound to amplify the effect of co-administered drugs, with a primary focus on oncology. Its biomechanical mode of action increases the local uptake of therapeutics from blood vessels into the surrounding tissue, including across the blood-brain barrier, without requiring drug reformulation. This non-invasive technology is designed to be compatible with standard ultrasound systems. The company's pipeline includes the ENACT study, a Phase 2 trial evaluating ACT® in patients with locally advanced pancreatic cancer, following the completion of the ACTIVATE Phase 1 study in patients with liver metastases.

Recent filings

Filing Released Lang Actions
EXACT THERAPEUTICS AS (“EXACT-Tx”, or “the Company” Euronext Growth: EXTX) - PROVIDES STRATEGIC BUSINESS UPDATE
Regulatory Filings Classification · 92% confidence The document is titled 'EXACT THERAPEUTICS AS PROVIDES STRATEGIC BUSINESS UPDATE' and details operational developments, clinical trial plans (ACTIVATE trial recommencement, new US trial in pancreatic cancer), expected regulatory filings (IND filing to FDA), scientific publication highlights (BBB permeability), and management changes (return of CSO). This content is characteristic of an announcement providing key updates on business strategy, operations, and scientific progress, rather than a formal regulatory report (like 10-K or IR) or a transcript. It fits best under the general category of Investor Relations updates that are not specifically earnings releases (ER) or capital changes (CAP). Given the options, this is a broad strategic update, which often falls under Investor Relations or a general announcement. Since it is not a formal financial report, a transcript, or a specific regulatory filing like DIRS or DIV, and it focuses on strategy and operations, it aligns most closely with an Investor Presentation (IP) if it were a presentation, or a general update. However, since it is a press release format detailing strategic direction and operational milestones, it is often classified as a general Investor Relations document. Comparing the definitions, it is not a formal 'Earnings Release' (ER) as it doesn't focus on period results, nor is it a 'Management Report' (MDA) which usually explains financial results. It is a strategic update announcement. In the absence of a specific 'Press Release' or 'Business Update' code, and given the focus on strategy and platform development, it is closest to an Investor Presentation (IP) in spirit, but since it's a text announcement, 'Regulatory Filings' (RNS) serves as the best general catch-all for non-standard, non-financial press releases, or we must select the closest fit. Given the high level of strategic and operational detail, it is a significant communication to investors. If we must choose from the list, and recognizing it's a press release detailing strategy, it is often grouped with Investor Presentations (IP) or general Regulatory Filings (RNS). Since it is a detailed update on strategy and pipeline, 'Investor Presentation' (IP) is a plausible fit if the content mirrors what would be in a presentation, but 'Regulatory Filings' (RNS) is the safest fallback for non-standard announcements. Let's re-evaluate: It is a press release announcing strategic direction, clinical progress, and management changes. This is a classic Investor Relations communication. Since 'IP' is defined as a 'Detailed presentation for investors focusing on financials, strategy, and market position,' and this document details strategy and pipeline progress, it is a strong candidate. I will classify it as IP as it is a detailed strategic communication aimed at investors, even if not strictly a slide deck.
2021-11-18 English
EXACT THERAPEUTICS AS (“EXACT-Tx”, or “the Company” Euronext Growth: EXTX) - PROVIDES STRATEGIC BUSINESS UPDATE
Earnings Release Classification · 90% confidence The document is titled "EXACT THERAPEUTICS AS (“EXACT-Tx”, or “the Company” Euronext Growth: EXTX) - PROVIDES STRATEGIC BUSINESS UPDATE". It details operational plans (clinical trial recommencement, new US trial filing timelines), scientific updates (preclinical data publication), and management changes (CSO return). This content is characteristic of an announcement providing key business and operational highlights rather than a full financial report (like 10-K or IR) or a formal transcript (CT). It aligns best with an Earnings Release (ER) which often includes strategic updates alongside results, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the focus on strategic updates, clinical progress, and management changes, it functions as a high-level update, similar to what might accompany an earnings announcement, but since it doesn't explicitly state financial results, it fits the general category of a significant corporate announcement. However, since it is a detailed update on strategy, trials, and personnel, and not just a brief notice of a report, it is not RPA/RNS based on the 'MENU VS MEAL' rule. It is most closely related to an Earnings Release (ER) which often contains these strategic elements, or potentially an Investor Presentation (IP) if it were structured as slides, but as text, ER is the closest fit for a periodic, high-level update. FY 2021
2021-11-18 English
EXACT THERAPEUTICS AS ANNOUNCES CHANGES TO THE MANAGEMENT TEAM
Board/Management Information Classification · 100% confidence The document explicitly announces changes to the management team, specifically stating that the CEO, Dr Rafiq Hasan, is stepping down and naming an Interim CEO (Dominic Moreland) and an Executive Chair (Dr Masha Strømme). This directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management.
2021-10-19 English
EXACT Therapeutics AS announces interim results for first half 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT 2021' and covers the 'HALF YEAR TO 30 JUNE 2021'. It contains comprehensive financial statements, including the Condensed Consolidated Statement of Comprehensive Income, Financial Position, Cash Flows, and Changes in Equity, along with management's operational review and a responsibility statement from the Board of Directors. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data for a period shorter than a full fiscal year. H1 2021
2021-09-22 English
EXACT Therapeutics AS announces interim results for first half 2021
Report Publication Announcement Classification · 100% confidence The document is a short announcement (approx. 1000 characters) stating that the interim results for the first half of 2021 have been released and provides a link to the company website to access the actual report. Per the 'Menu vs Meal' rule, since this is an announcement of a report rather than the report itself, it is classified as a Report Publication Announcement. H1 2021
2021-09-22 English
EXACT THERAPEUTICS TO PRESENT AT PARETO SECURITIES 12th ANNUAL HEALTHCARE CONFERENCE
Report Publication Announcement Classification · 99% confidence The document is a short announcement stating that the CEO of Exact Therapeutics will be presenting at the 'Pareto Securities 12th Annual Healthcare Conference' on a specific date. This is not a full financial report (like 10-K or IR), nor is it a transcript (CT) or a formal regulatory filing detailing results (ER, AR). It is an announcement about the company's participation in an investor-facing event, which falls under Investor Presentation (IP) or potentially a general announcement. Since the content is about presenting company information (strategy, technology, platform) to investors at a conference, 'Investor Presentation' (IP) is the most fitting category, even though this specific text is just the announcement of the presentation, not the presentation slides themselves. Given the context of financial reporting databases, announcements about investor events are often grouped with investor materials. However, applying the 'MENU VS MEAL' rule strictly, this is an announcement *about* an event where a presentation will occur. If the document were the actual presentation slides, IP would be correct. As it is a brief press release announcing participation in a conference, it is closest to a general announcement or a precursor to an investor presentation. Given the options, and recognizing that investor conferences are key investor relations activities, IP is the best fit over the general fallback RNS, as it directly relates to investor engagement.
2021-08-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.